Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia

Authors

  • R. Zakharyan,

    1. Laboratory of Macromolecular Complexes, Institute of Molecular Biology, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
    2. Laboratory of Immunogenomics and Immunoproteomics, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
    Search for more papers by this author
  • M. Petrek,

    1. Laboratory of Immunogenomics and Immunoproteomics, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
    Search for more papers by this author
  • A. Arakelyan,

    1. Laboratory of Macromolecular Complexes, Institute of Molecular Biology, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
    Search for more papers by this author
  • F. Mrazek,

    1. Laboratory of Immunogenomics and Immunoproteomics, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
    Search for more papers by this author
  • S. Atshemyan,

    1. Laboratory of Macromolecular Complexes, Institute of Molecular Biology, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
    Search for more papers by this author
  • A. Boyajyan

    Corresponding author
    1. Laboratory of Macromolecular Complexes, Institute of Molecular Biology, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
    Search for more papers by this author

Anna Boyajyan

Laboratory of Macromolecular Complexes

Institute of Molecular Biology

National Academy of Sciences of the Republic of Armenia

Yerevan

Armenia

Tel: +3 741 028 2061

Fax: +3 741 028 2061

e-mail: aboyajyan@sci.am

Abstract

Schizophrenia is a severe psychiatric disease with inflammatory component. Several studies indicated the increased blood levels of proinflammatory interleukin-6 cytokine in schizophrenia. However, only limited studies explored the relationship between excess production and genetic variations of this cytokine in schizophrenia, and the results were controversial. Here, we investigated possible association of the interleukin-6 gene (IL6) rs1800795 (–174G/C) polymorphism with schizophrenia and relationship between this polymorphism and interleukin-6 protein (IL-6) blood levels. This polymorphism was found by other researchers to associate with different transcription rates and different plasma levels of IL-6. A total of 208 unrelated Armenians were genotyped by polymerase chain reaction with sequence-specific primers, and IL-6 levels were assessed by enzyme-linked immunosorbent assay. The IL6 rs1800795 alleles and genotypes in both groups were in Hardy–Weinberg (H–W) equilibrium. We found that rs1800795*C allele [38% vs 24%, P = 0.002, odds ratio (OR) = 1.95, 95% confidence interval (CI): 1.18–2.14] and its carriers (62% vs 42%, P = 0.003, OR = 2.28, 95% CI: 1.13–1.94) were more frequent in patients than in controls. IL-6 in patients was 1.5-fold higher than in controls (mean ± SD: 6.41 ± 2.47 pg/ml vs 4.15 ± 1.42 pg/ml, P = 1.9E–19). In both groups, higher IL-6 in rs1800795 GG compared to rs1800795*C allele carriers was observed (GG vs GC + CC, patients: 7.02 ± 2.83 pg/ml vs 5.39 ± 1.2 pg/ml, P = 0.0006; controls: 5.21 ± 1.17 pg/ml vs 3.38 ± 1.03 pg/ml, P = 1.6E–15). In conclusion, we report an association of IL6 rs1800795 and higher IL-6 with schizophrenia. We also conclude that IL6 rs1800795*C allele is linked to increased IL-6 blood levels and may be a risk factor for schizophrenia development at least in Armenian population.

Ancillary